Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Olanzapine

FDA-approved product (tablet, oral), marketed as Olanzapine, Zyprexa, Zyprexa Zydis and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Olanzapine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Agitation
  • Bipolar disorder
  • Bipolar I disorder
  • Major depressive disorder
  • Mental or behavioural disorder
  • Psychosis
  • Schizoaffective disorder
  • Schizophrenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Diazepines, oxazepines, thiazepines and oxepines
FDA pharmacologic class
Atypical Antipsychotic FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA43.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Olanzapine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.5 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Olanzapine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy

    NCT01609153 · start 2012-06

    Registered record
    Registry ID
    NCT01609153
    Conditions
    Schizophrenia; Schizoaffective Disorder
    Interventions
    Olanzapine; Amisulpride; Olanzapine and Amisulpride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-06
    Completion
    2019-04
    Enrolment
    328

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder
    InterventionOlanzapine; Amisulpride; Olanzapine and Amisulpride
    PhasePhase 4
    Registry statusCompleted

  • The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia

    NCT04076371 · start 2012-01

    Registered record
    Registry ID
    NCT04076371
    Conditions
    Schizophrenia
    Interventions
    olanzapine-sertraline combination; only olanzapine; risperidone-sertraline combination; only risperidone; paliperidone-sertraline combination; only paliperidone; ziprasidone-sertraline combination; only ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-01
    Completion
    2018-12
    Enrolment
    1,640

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    Interventionolanzapine-sertraline combination; only olanzapine; risperidone-sertraline combination; only risperidone +4 more
    PhaseNot applicable
    Registry statusCompleted

  • Bioequivalence Study of Olanzapine Tablets, 5 mg of Dr. Reddy's Under Fasting Conditions

    NCT01503398 · start 2011-08

    Registered record
    Registry ID
    NCT01503398
    Conditions
    Fasting
    Interventions
    Olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-08
    Completion
    2011-09
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFasting
    InterventionOlanzapine
    PhasePhase 1
    Registry statusCompleted

  • PHARMO Institute Seroquel Safety Study

    NCT01342120 · start 2010-09

    Registered record
    Registry ID
    NCT01342120
    Conditions
    Schizophrenia; Major Depressive Disorder; Bipolar Disorder; Generalized Anxiety Disorder
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-09
    Completion
    2010-11
    Enrolment
    18,325

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Major Depressive Disorder; Bipolar Disorder; Generalized Anxiety Disorder
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Olanzapine Versus Placebo for Outpatients With Anorexia Nervosa

    NCT01170117 · start 2010-08

    Registered record
    Registry ID
    NCT01170117
    Conditions
    Anorexia Nervosa
    Interventions
    Olanzapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-08
    Completion
    2017-06
    Enrolment
    152

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnorexia Nervosa
    InterventionOlanzapine; Placebo
    PhaseNot applicable
    Registry statusCompleted

  • Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone

    NCT00910988 · start 2009-02

    Registered record
    Registry ID
    NCT00910988
    Conditions
    Hyperglycemia; Hyperlipidemia
    Interventions
    Olanzapine; Ziprasidone
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-02
    Completion
    2012-06
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHyperglycemia; Hyperlipidemia
    InterventionOlanzapine; Ziprasidone
    PhaseNot applicable
    Registry statusCompleted

  • Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects

    NCT00734435 · start 2008-09

    Registered record
    Registry ID
    NCT00734435
    Conditions
    Schizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
    Interventions
    zonisamide SR plus olanzapine; Placebo plus olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2008-09
    Completion
    2008-12
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia; Schizoaffective Disorder; Schizophreniform Disorder
    Interventionzonisamide SR plus olanzapine; Placebo plus olanzapine
    PhasePhase 2
    Registry statusTerminated

  • Safety and Efficacy of Olanzapine in the Long-term Treatment for Bipolar I Disorder, Depressed

    NCT00618748 · start 2008-02

    Registered record
    Registry ID
    NCT00618748
    Conditions
    Bipolar I Disorder
    Interventions
    Olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-02
    Completion
    2010-09
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar I Disorder
    InterventionOlanzapine
    PhasePhase 3
    Registry statusCompleted

  • Juvenile Bipolar Disorder Outpatient Program

    NCT01000402 · start 2008-02

    Registered record
    Registry ID
    NCT01000402
    Conditions
    Bipolar Disorder; Attention Deficit Disorder With Hyperactivity
    Interventions
    Psychopharmacotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-02
    Completion
    2014-11
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder; Attention Deficit Disorder With Hyperactivity
    InterventionPsychopharmacotherapy
    PhasePhase 4
    Registry statusUnknown

  • Sertindole in Asian Patients With Schizophrenia

    NCT00864045 · start 2007-03

    Registered record
    Registry ID
    NCT00864045
    Conditions
    Schizophrenia
    Interventions
    Sertindole; Olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-03
    Completion
    2008-05
    Enrolment
    394

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionSertindole; Olanzapine
    PhasePhase 3
    Registry statusCompleted

  • Ondansetron With Olanzapine for the Treatment of Alcohol Dependence: A Preliminary Clinical Trial

    NCT00678457 · start 2007-01

    Registered record
    Registry ID
    NCT00678457
    Conditions
    Alcohol Dependence
    Interventions
    Ondansetron; Olanzapine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-01
    Completion
    2008-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Dependence
    InterventionOndansetron; Olanzapine; Placebo
    PhasePhase 2
    Registry statusCompleted

  • A Study to Evaluate the Efficacy and Safety of Risperidone for the Prevention of Mood Episodes in the Treatment of Patients With Bipolar I Disorder

    NCT00391222 · start 2006-11

    Registered record
    Registry ID
    NCT00391222
    Conditions
    Bipolar Disorder
    Interventions
    Olanzapine; Placebo; Risperidone Long Acting Injectable (LAI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-11
    Completion
    2009-04
    Enrolment
    585

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar Disorder
    InterventionOlanzapine; Placebo; Risperidone Long Acting Injectable (LAI)
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia

    NCT00396565 · start 2006-07

    Registered record
    Registry ID
    NCT00396565
    Conditions
    Schizophrenia
    Interventions
    ER OROS paliperidone; Placebo; Olanzapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-07
    Completion
    2007-11
    Enrolment
    394

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSchizophrenia
    InterventionER OROS paliperidone; Placebo; Olanzapine
    PhasePhase 3
    Registry statusCompleted

  • Effects of Modafinil on Olanzapine Weight Gain

    NCT00636896 · start 2006-07

    Registered record
    Registry ID
    NCT00636896
    Conditions
    Weight Gain
    Interventions
    Olanzapine plus modafinil; Olanzapine plus placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-07
    Completion
    2007-08
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionWeight Gain
    InterventionOlanzapine plus modafinil; Olanzapine plus placebo
    PhaseNot applicable
    Registry statusCompleted

  • Metabolic Profile and Anthropometric Changes in Schizophrenia

    NCT00534183 · start 2006-06

    Registered record
    Registry ID
    NCT00534183
    Conditions
    Metabolic Syndrome; Diabetes; Obesity
    Interventions
    Olanzapine; Risperidone; Haloperidol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2006-06
    Completion
    2006-12
    Enrolment
    2,006

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetabolic Syndrome; Diabetes; Obesity
    InterventionOlanzapine; Risperidone; Haloperidol
    PhaseNot applicable
    Registry statusCompleted